Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of remibrutinib in adults with papulopustular rosacea
CTR20262818Phase 2Active
- Sponsor
- 不适用/ 诺华（中国）生物医学研究有限公司
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of remibrutinib in papulopustular rosacea, sponsored by 不适用/ 诺华（中国）生物医学研究有限公司. Started Aug 2026; status: active.
02
Drugs
remibrutinib
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on CTR20262818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262818.